Symbol Lookup

Friday September 04, 2015 4:58 PM ET. Data delayed 15 minutes.
7.37
0.12 (1.66%)
Bid/Lots
7.02/10
Ask/Lots
8.09/6
Open/Prev Close
7.20/7.25
Day Range
7.00-7.43
52-Week Range
4.40-15.24
Vol/Avg Daily Vol
53.5K/97.7K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference
7:00AM ET on Wednesday Sep 02, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb(R) blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, announced that CEO...

CytoSorbents Shares Gain 11% - Posts Q2 EPS, Revenue Beat
1:50PM ET on Friday Aug 14, 2015 by MT Newswires
01:50 PM EDT, 08/14/2015 (MT Newswires) -- CytoSorbents Corporation (CTSO) rose in Friday's afternoon trade after the company reported better-than-expected financial results for Q2. Shares are up 10.5% at $6.83, with a 52-week range of $4.40 - $1...
CytoSorbents Reports Steady Growth in Q2 2015
4:15PM ET on Thursday Aug 13, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb(R) blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, reported financial...

Saudi Food and Drug Authority Approves CytoSorb(R)
8:00AM ET on Monday Aug 10, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company commercializing its CytoSorb(R) extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, today announce...

CytoSorbents to Report Q2 2015 Operating and Financial Results
8:00AM ET on Thursday Aug 06, 2015 by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy company commercializing its CytoSorb(R) extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, will report Q2...

Company Information

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company's purification technologies are based on biocompatible, porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's product CytoSorb is approved in the European Union as an extracorporeal cytokine filter, designed to reduce the cytokine storm that could cause inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. In addition, CytoSorb can be used in conditions, such as cardiac surgery, autoimmune disease flares, among others.

CONTACT INFORMATION

Headquarters7 Deerpark Dr Ste K
MONMOUTH JUNCTION, NJ, United States 08852-1921
Phone973-329-8885
Fax732-329-8650

EXECUTIVE OFFICERS

Chairman of the BoardAl Kraus
President, Chief Executive Officer, DirectorPhillip Chan
Chief Financial OfficerKathleen Bloch
Chief Operating OfficerVincent Capponi
Chief Medical OfficerRobert Bartlett

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$181.6MBeta-0.18
Revenue (TTM)$3.7MEPS$-0.84
Shares Out.25.0MBook Value$0.17
Dividend Yield0.00%P/E--
Annual Dividend Rate0.00 USDPrice/Sales (TTM)48.8
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin-260.02%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample